These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

393 related items for PubMed ID: 23414588

  • 1. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
    Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.
    Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
    [Abstract] [Full Text] [Related]

  • 2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
    Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, Untch M, Smith I, Baselga J, Jackisch C, Cameron D, Mano M, Pedrini JL, Veronesi A, Mendiola C, Pluzanska A, Semiglazov V, Vrdoljak E, Eckart MJ, Shen Z, Skiadopoulos G, Procter M, Pritchard KI, Piccart-Gebhart MJ, Bell R, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
    [Abstract] [Full Text] [Related]

  • 3. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
    Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
    [Abstract] [Full Text] [Related]

  • 4. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
    Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M.
    Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
    [Abstract] [Full Text] [Related]

  • 5. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team.
    Lancet; 2007 Jan 06; 369(9555):29-36. PubMed ID: 17208639
    [Abstract] [Full Text] [Related]

  • 6. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
    de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.
    J Clin Oncol; 2014 Jul 10; 32(20):2159-65. PubMed ID: 24912899
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
    Zhang P, Yu SY, Shen ZZ, Song ST, Guan ZZ, Jiao SC, Zheng S, Xu GW, Feng FY.
    Zhonghua Yi Xue Za Zhi; 2012 Dec 18; 92(47):3345-9. PubMed ID: 23328596
    [Abstract] [Full Text] [Related]

  • 9. 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.
    Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, Castro G, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, McFadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet; 2017 Mar 25; 389(10075):1195-1205. PubMed ID: 28215665
    [Abstract] [Full Text] [Related]

  • 10. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
    Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, Michiara M, Silini EM, Ardizzoni A.
    Cancer; 2011 May 01; 117(9):1837-46. PubMed ID: 21509760
    [Abstract] [Full Text] [Related]

  • 11. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou A, Smith I.
    Breast; 2011 Oct 01; 20 Suppl 3():S158-61. PubMed ID: 22015286
    [Abstract] [Full Text] [Related]

  • 12. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
    Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, Moliterni A, Vazquez F, Byakhov MJ, Lichinitser M, Climent MA, Ciruelos E, Ojeda B, Mansutti M, Bozhok A, Magazzù D, Heinzmann D, Steinseifer J, Valagussa P, Baselga J.
    Lancet Oncol; 2014 May 01; 15(6):640-7. PubMed ID: 24657003
    [Abstract] [Full Text] [Related]

  • 13. Long-term outcome and pattern of relapse after neoadjuvant chemotherapy in patients with human epidermal growth factor receptor 2-positive primary breast cancer.
    Shimizu C, Masuda N, Yoshimura K, Tsuda H, Mano M, Ando M, Tamura K, Fujiwara Y.
    Jpn J Clin Oncol; 2009 Aug 01; 39(8):484-90. PubMed ID: 19477897
    [Abstract] [Full Text] [Related]

  • 14. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
    Liberato NL, Marchetti M, Barosi G.
    J Clin Oncol; 2007 Feb 20; 25(6):625-33. PubMed ID: 17308267
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?
    Vesely P, Melichar B.
    Neoplasma; 2008 Feb 20; 55(5):375-80. PubMed ID: 18665746
    [Abstract] [Full Text] [Related]

  • 17. Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trial.
    Partridge AH, Gelber S, Piccart-Gebhart MJ, Focant F, Scullion M, Holmes E, Winer EP, Gelber RD.
    J Clin Oncol; 2013 Jul 20; 31(21):2692-8. PubMed ID: 23752109
    [Abstract] [Full Text] [Related]

  • 18. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
    Leyland-Jones B.
    J Clin Oncol; 2009 Nov 01; 27(31):5278-86. PubMed ID: 19770385
    [Abstract] [Full Text] [Related]

  • 19. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
    Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL.
    Ann Oncol; 2013 Jun 01; 24(6):1526-33. PubMed ID: 23463626
    [Abstract] [Full Text] [Related]

  • 20. 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
    Goldhirsch A, Gelber RD, Piccart-Gebhart MJ, de Azambuja E, Procter M, Suter TM, Jackisch C, Cameron D, Weber HA, Heinzmann D, Dal Lago L, McFadden E, Dowsett M, Untch M, Gianni L, Bell R, Köhne CH, Vindevoghel A, Andersson M, Brunt AM, Otero-Reyes D, Song S, Smith I, Leyland-Jones B, Baselga J, Herceptin Adjuvant (HERA) Trial Study Team.
    Lancet; 2013 Sep 21; 382(9897):1021-8. PubMed ID: 23871490
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.